BioCardia Inc

### Capital Structure and Liquidity BioCardia has a negative net equity position of $1.96 million, indicating a significant deficit in its capital structure. The company's cash and equivalents amount to $1.42 million, which is insufficient to cover its total liabilities of $4.85 million, resulting in a current ratio of 0.39. This low liquidity position suggests the company may face challenges in meeting its short-term obligations without external financing.

### Profitability and Returns The company reported a net loss of $1.65 million and an operating loss of $1.65 million, reflecting poor profitability. The return on equity (ROE) is 0.8394, which is exceptionally low, and the return on assets (ROA) is -0.5696, indicating that the company is not generating returns from its asset base. These metrics are well below industry norms for biotechnology firms, which typically require significant R&D investment before achieving profitability.

### Segments and Geographic Exposure BioCardia's financial data does not provide detailed segment or geographic revenue breakdowns. However, the company's primary operations are likely concentrated in the United States, given its listing on the NASDAQ and the absence of international revenue disclosures. This lack of diversification increases its exposure to domestic market risks.

### Growth Trajectory The company's revenue for the latest period is $3.00 million, but it is operating at a significant loss. Analysts have provided a mean price target of $15.50, which is substantially higher than the current market price of $1.09. This suggests that analysts expect a significant turnaround in the company's performance, although the current financials do not support such optimism.

### Risk Factors The risk assessment indicates low liquidity and dilution risks, but the company's negative net equity and high operating losses pose significant financial risks. The absence of long-term debt is a positive factor, but the company's reliance on cash reserves to fund operations is a concern. There are no immediate filing-based liquidity or dilution flags, but the company's financial position remains precarious.

### Recent Events Recent filings and transcripts do not indicate any major events that would significantly impact the company's financial position. However, the company's ongoing losses and limited cash reserves suggest that it may need to secure additional financing in the near future to continue operations.

Analysts project 1,571% upside to a mean price target of $15.50, signaling strong institutional confidence in future value.

Return on equity of 0.84 ranks as best-in-class compared to the biotechnology cohort median of -0.22.

Cash conversion ratio of 1.73 is best-in-class, significantly outperforming the cohort median of 0.87.

The company maintains zero long-term debt across all reported fiscal years, eliminating interest expense obligations.

Dilution, liquidity, and credit risks are all assessed at low levels, suggesting a stable risk profile.

Net margin of -549% places the company in the bottom quartile of its biotechnology cohort peers.

Operating margin of -550% ranks in the bottom quartile, reflecting severe inefficiency relative to industry standards.

Free cash flow remains deeply negative at -$8.2 million in fiscal 2026, requiring continuous capital infusion.

Book value is negative at -$1.96 million, indicating accumulated losses have eroded shareholder equity entirely.

Revenue $0.00; Operating income +13,3% YoY.

• ▍Revenue $0.00
• ▍Operating income +13,3% YoY
• ▍Net income +13,6% YoY
• ▍Free cash flow +12,9% YoY

Operating income +15,3% YoY; Net income +14,6% YoY.

• ▍Operating income +15,3% YoY
• ▍Net income +14,6% YoY
• ▍Free cash flow +14,2% YoY

Revenue $0.00, −100,0% YoY; Operating income −24,4% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −24,4% YoY
• ▍Net income −24,5% YoY
• ▍Free cash flow −25,2% YoY

Revenue $0.00; Operating income -$2.3M.

• ▍Revenue $0.00
• ▍Operating income -$2.3M

Revenue $0.00; Operating income -$1.8M.

• ▍Revenue $0.00
• ▍Operating income -$1.8M

Revenue $3.0k; Operating income -$1.6M.

• ▍Revenue $3.0k
• ▍Operating income -$1.6M
• ▍Net margin -54866.7%

Revenue $0.00, −100,0% YoY; Operating income −3,5% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −3,5% YoY
• ▍Net income −3,5% YoY
• ▍Free cash flow −4,1% YoY

Revenue $58.0k, −87,8% YoY; Operating income +31,3% YoY.

• ▍Revenue $58.0k, −87,8% YoY
• ▍Operating income +31,3% YoY
• ▍Net income +31,3% YoY
• ▍Free cash flow +31,4% YoY
• ▍Net margin -13700.0%

Revenue $477.0k, −64,7% YoY; Operating income +2,2% YoY.

• ▍Revenue $477.0k, −64,7% YoY
• ▍Operating income +2,2% YoY
• ▍Net income +2,8% YoY
• ▍Free cash flow +3,3% YoY
• ▍Net margin -2425.8%

Revenue $1.4M, +33,2% YoY; Operating income +5,8% YoY.

• ▍Revenue $1.4M, +33,2% YoY
• ▍Operating income +5,8% YoY
• ▍Net income +5,7% YoY
• ▍Free cash flow +6,2% YoY
• ▍Net margin -880.7%

Revenue $1.0M; Operating income -$12.6M.

• ▍Revenue $1.0M
• ▍Operating income -$12.6M
• ▍Net margin -1243.6%